Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (241-250 of 484) with videos related to

Pageof 49
Sort By:
Journal of Geriatric Oncology|August 3, 2020
A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancerScott D Ramsey, Ingrid J Hall, Judith Lee Smith, et al.
Urology|November 10, 2007
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mLEdith Canby-Hagino, Javier Hernandez, Timothy C Brand, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionM Scott Lucia, Amy K Darke, Phyllis J Goodman, et al.
American Journal of Epidemiology|April 27, 2011
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trialTheodore M Brasky, Cathee Till, Emily White, et al.
The Journal of Urology|March 27, 2007
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Kathryn B Arnold, Jeannette M Schenk, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2007
Assessment of 54 biomarkers for biopsy-detectable prostate cancerDipen J Parekh, Donna Pauler Ankerst, Jacques Baillargeon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794Gregory P Swanson, Michael A Hussey, Catherine M Tangen, et al.
Urology|December 16, 2006
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened populationDipen J Parekh, Donna Pauler Ankerst, Betsy A Higgins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention TrialIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
American Journal of Epidemiology|October 24, 2008
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Jeannette M Schenk, YoonJu Song, et al.
Pageof 49

Showing results (241-250 of 484) with videos related to

Sort By:
Pageof 49
Journal of Geriatric Oncology|August 3, 2020
A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancerScott D Ramsey, Ingrid J Hall, Judith Lee Smith, et al.
Urology|November 10, 2007
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mLEdith Canby-Hagino, Javier Hernandez, Timothy C Brand, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionM Scott Lucia, Amy K Darke, Phyllis J Goodman, et al.
American Journal of Epidemiology|April 27, 2011
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trialTheodore M Brasky, Cathee Till, Emily White, et al.
The Journal of Urology|March 27, 2007
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Kathryn B Arnold, Jeannette M Schenk, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2007
Assessment of 54 biomarkers for biopsy-detectable prostate cancerDipen J Parekh, Donna Pauler Ankerst, Jacques Baillargeon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794Gregory P Swanson, Michael A Hussey, Catherine M Tangen, et al.
Urology|December 16, 2006
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened populationDipen J Parekh, Donna Pauler Ankerst, Betsy A Higgins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention TrialIan M Thompson, Donna Pauler Ankerst, Chen Chi, et al.
American Journal of Epidemiology|October 24, 2008
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal, Jeannette M Schenk, YoonJu Song, et al.
Pageof 49